Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 6 of 24 for:    sarcoma | Recruiting, Not yet recruiting, Available Studies | Interventional Studies | Phase 3

Preoperative vs Postoperative IMRT for Extremity/Truncal STS

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02565498
Recruitment Status : Recruiting
First Posted : October 1, 2015
Last Update Posted : February 15, 2019
Sponsor:
Collaborator:
Princess Margaret Hospital, Canada
Information provided by (Responsible Party):
Mount Sinai Hospital, Canada

Brief Summary:
This study is designed to determine if preoperative image guided radiation therapy (IGRT) delivered using intensity modulated radiation therapy (IMRT) followed by surgery results in similar short-term wound healing complications as surgery followed by postoperative IGRT in patients with extremity or truncal soft tissue sarcoma. Half of the patients will receive preoperative radiotherapy, half will receive postoperative radiotherapy.

Condition or disease Intervention/treatment Phase
Adult Soft Tissue Sarcoma Radiation: Preoperative intensity modulated radiation therapy Radiation: Postoperative intensity modulated radiation therapy Phase 3

Detailed Description:
Perioperative RT in addition to surgery is widely accepted as standard management for soft tissue sarcoma (STS) of the extremity and trunk. However, controversy remains as to whether RT should be delivered preoperatively or postoperatively. While both confer similar rates of local control, preoperative RT leads to a decrease in late tissue morbidities such as fibrosis, limb edema, joint stiffness and fracture as compared to postoperative RT. The reasons for this are likely multifactorial, but are in part related to total dose delivered (50 Gray (GY) preoperatively and 60-66 Gy postoperatively) and, based on a previous National Cancer Institute (Canada) Phase III randomized controlled trial, the much larger volume treated in the postoperative setting compared to that in the preoperative setting. The optimal radiation dose used in the postoperative setting is unknown but has been developed empirically and doses of 60-66 Gy are generally employed.However, investigators in Norway/Sweden and France have found equivalent local control rates for patients with negative surgical margins treated with 50 GY postoperativelyThe main concern with preoperative RT has centered on the risk of an increased rate of delayed wound healing and major wound complications. Although some studies suggest it may be possible to reduce the incidence of acute wound healing complications associated with pre-operative radiation than previously seen in the 2D RT era, this has yet to be tested in the phase III setting. IG-IMRT allows a much higher degree of conformality and accurate delivery of dose to the tumour while sparing surrounding normal tissue. This may allow similar rates of acute wound healing complications for pre- and postoperative RT in the treatment of STS.

Layout table for study information
Study Type : Interventional
Estimated Enrollment : 206 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase III Study of Preoperative vs Postoperative Intensity Modulated Radiation Therapy For Truncal/Extremity Soft Tissue Sarcoma
Study Start Date : June 2016
Estimated Primary Completion Date : April 2020
Estimated Study Completion Date : December 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Preoperative Radiation Therapy (Arm A)
Preoperative intensity modulated radiation therapy followed by surgery
Radiation: Preoperative intensity modulated radiation therapy
50 Gy delivered in 25 fractions 4-6 weeks prior to surgical excision

Experimental: Postoperative Radiation Therapy (Arm B)
Surgery followed by postoperative intensity modulated radiation therapy
Radiation: Postoperative intensity modulated radiation therapy
Surgery followed by 50 Gy delivered in 25 fractions within 6 weeks of surgery for patients with negative margins; for patients with positive margins a boost of 16 Gy in 8 fractions will be added.




Primary Outcome Measures :
  1. Incidence of acute wound healing complications [ Time Frame: 120 days post surgery ]
    • Secondary operations required for wound treatment (debridement, secondary closure procedures such as rotationplasty, free flaps or skin grafts);
    • Readmission to hospital for wound care;
    • Invasive procedures required for wound care (drainage of hematoma, seroma or infected wound collection);
    • Deep wound packing required at any time (deep packing defined as packing deep to dermis in an area of dehisced wound) to an area of the wound measuring at least 2 cm in length;
    • Prolonged dressing changes, including packing of the wound for greater than six weeks from wound breakdown;
    • Repeat surgery for revision of a split thickness skin graft or requirement for wet dressings for longer than four weeks. (It is permissible for a patient to protect a totally epithelialized skin graft with a dry dressing without declaring a major wound complication)
    • Use of vacuum-assisted closure (VAC)


Secondary Outcome Measures :
  1. Acute Radiation Toxicity [ Time Frame: Once per week from the start of radiotherapy until its completion (5 weeks in total), then 1 week preop for Group 1; 4 weeks post completion of treatment for Group 2 ]
    Acute radiation skin toxicity will be documented according to the Radiotherapy Oncology Group (RTOG) Acute Radiation Morbidity Scoring Criteria.

  2. Late Radiation Toxicity- RTOG Late Radiation Morbidity [ Time Frame: Every 3 months, from 3 months postop for Group 1 and 3 months post RT for Group 2, for 2 years, then 4 monthly for 1 year, then 6 monthly to 5 years. ]
    Late radiation morbidity to skin, subcutaneous tissue, bone and joints will be documented according to the RTOG/EORTC Late Radiation Morbidity Scoring Scheme.

  3. Late Radiation Toxicity- Common Toxicity Criteria [ Time Frame: Every 3 months, from 3 months postop for Group 1 and 3 months post RT for Group 2, for 2 years, then 4 monthly for 1 year, then 6 monthly to 5 years. ]
    Late radiation morbidity to skin, subcutaneous tissue, bone and joints will be documented according to the Common Toxicity Criteria v4.0

  4. Late Radiation Toxicity- Limb Edema [ Time Frame: Every 3 months, from 3 months postop for Group 1 and 3 months post RT for Group 2, for 2 years, then 4 monthly for 1 year, then 6 monthly to 5 years. ]
    Peripheral limb edema will be documented according to the Late Limb Edema Scoring Criteria.

  5. Limb Function [ Time Frame: Within 14 days of randomization, then at 3 and 6 months, 1, 2, 3 and 5 years postop. ]
    Limb function will be documented according to the Musculoskeletal Tumor Society Rating Scale.

  6. Patient function [ Time Frame: Within 14 days of randomization, then at 3 and 6 months, 1, 2, 3 and 5 years postop. ]
    Patient function will be documented according to the patient completed Toronto Extremity Salvage Score (TESS)

  7. Overall Survival [ Time Frame: Surgery Date until 5 years postoperative or death, whichever occurs first ]
    Overall patient survival in months during the study period

  8. Local recurrence-free survival [ Time Frame: Surgery date until 5 years postoperative or local recurrence, whichever occures first. ]
    Patient survival without a local recurrence in months during the study period.

  9. Metastasis-free survival [ Time Frame: Surgery date until 5 years postoperative or systemic recurrence, whichever occures first. ]
    Patient survival without systemic metastases in months during the study period.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Histologically proven soft tissue sarcoma of the extremity or trunk following review by local reference pathologist.
  2. Deemed appropriate for preoperative or postoperative radiotherapy and conservative surgery following patient assessment by a radiation oncologist and surgical oncologist.
  3. Lesion is primary or locally recurrent. Patient may have undergone excisional biopsy with positive margins at a referring hospital and are eligible following discussion among the surgical oncologists and radiation oncologists that IMRT is an acceptable treatment for that case.
  4. Eastern Cooperative Oncology Group (ECOG) score 0-3
  5. Patient is aged 18years or older.
  6. Patient is able to provide informed consent
  7. Patient is available for treatment and follow-up.

Exclusion Criteria:

  1. Benign histology.
  2. Prior malignancy within the previous five years or concurrent malignancy with the exception of adequately treated basal cell carcinoma of the skin or carcinoma in-situ of the cervix.
  3. Prior radiotherapy to the target site
  4. Planned chemotherapy for (neo)adjuvant treatment
  5. Conservative surgery to the target site
  6. Presence of regional nodal disease or unequivocal distant metastases.
  7. Other major medical illness deemed to preclude safe administration of protocol treatment or required follow-up.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02565498


Contacts
Layout table for location contacts
Contact: Anthony Griffin, MSc (416) 586-5975 anthony.griffin@sinaihealthsystem.ca
Contact: Colleen Dickie, MSc (416) 946-2000 ext 3467 colleen.dickie@rmp.uhn.on.ca

Locations
Layout table for location information
United States, Massachusetts
Dana Farber Cancer Institute Recruiting
Boston, Massachusetts, United States, 02215
Contact: Cierra Zaslowe-Dude    617-582-8987    Cierra_Zaslowe-Dude@dfci.harvard.edu   
Contact: Thomas Johnson    617-582-8977    thomas_johnson@dfci.harvard.edu   
Principal Investigator: Elizabeth Baldini, MD         
Canada, Ontario
Mount Sinai Hospital Recruiting
Toronto, Ontario, Canada, M5G 1X5
Contact: Anthony Griffin, MSc    (416) 586-5975    anthony.griffin@sinaihealthsystem.ca   
Principal Investigator: Peter Ferguson, MD         
Sub-Investigator: Jay Wunder, MD         
Princess Margaret Cancer Centre Recruiting
Toronto, Ontario, Canada, M5G 2M9
Contact: Colleen Dickie, MSc    (416) 946-4501 ext 3467    colleen.dickie@rmp.uhn.on.ca   
Contact: Anthony Griffin, MSc    (416) 586-5975    anthony.griffin@sinaihealthsystem.ca   
Principal Investigator: Peter Chung, MD         
Sub-Investigator: Brian O'Sullivan, MD         
Sub-Investigator: Charles Catton, MD         
Sub-Investigator: David Shultz, MD         
Canada, Quebec
Hopital Maisonneuve-Rosemont Recruiting
Montreal, Quebec, Canada, H1T 2M4
Contact: Hugo St.-Yves, MSc    1-514-252-3400 ext 4428    hstyves.hmr@ssss.gouv.qc.ca   
Contact: Janie Barry, MSc    1-514-252-3400 ext 4428    jbarry.hmr@ssss.gouv.qc.ca   
Principal Investigator: Nader Khaouam, MD         
Sub-Investigator: Sophie Mottard, MD         
Sponsors and Collaborators
Mount Sinai Hospital, Canada
Princess Margaret Hospital, Canada
Investigators
Layout table for investigator information
Principal Investigator: Peter Ferguson, MD, FRCSC MOUNT SINAI HOSPITAL
Principal Investigator: Peter Chung, MD Princess Margaret Cancer Centre

Layout table for additonal information
Responsible Party: Mount Sinai Hospital, Canada
ClinicalTrials.gov Identifier: NCT02565498     History of Changes
Other Study ID Numbers: OCREB # 15-070
First Posted: October 1, 2015    Key Record Dates
Last Update Posted: February 15, 2019
Last Verified: February 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Mount Sinai Hospital, Canada:
Soft tissue sarcoma
Extremity
Preoperative radiotherapy
Postoperative radiotherapy

Additional relevant MeSH terms:
Layout table for MeSH terms
Sarcoma
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms